Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Planchard D, Cozic N, Mosele MF, Corcos N, Le Bescond L, Pradat Y, Ghigna MR, Nachabeh G, Alfaro A, Catelain C, Job B, Mami-Chouaib F, Badel S, Corgnac S, Farace F, Oulhen M, Kannouche P, Ngoc Tran DT, Droin N, Wislez M, Chouaid C, Curcio H, Cousin S, Mascaux C, Cadranel J, Geier M, Cheikh-Hussin R, Guyader P, Signolle N, Godefroy K, Talbot H, Vakalopoulou M, Christodoulidis S, Bernard E, Koudou Y, Camara V, Belarkemi A, Klein A, Morretton JP, East P, Chiaverelli R, Zwirtes R, Michiels S, Barlesi F, André F, Montagnac G, Pistilli B

Open source

DOI
10.1016/j.ccell.2026.03.017
Published
2026 Jun 8
Container
Cancer cell
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ccell.2026.03.017,
  title = {Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.},
  author = {Planchard D and Cozic N and Mosele MF and Corcos N and Le Bescond L and Pradat Y and Ghigna MR and Nachabeh G and Alfaro A and Catelain C and Job B and Mami-Chouaib F and Badel S and Corgnac S and Farace F and Oulhen M and Kannouche P and Ngoc Tran DT and Droin N and Wislez M and Chouaid C and Curcio H and Cousin S and Mascaux C and Cadranel J and Geier M and Cheikh-Hussin R and Guyader P and Signolle N and Godefroy K and Talbot H and Vakalopoulou M and Christodoulidis S and Bernard E and Koudou Y and Camara V and Belarkemi A and Klein A and Morretton JP and East P and Chiaverelli R and Zwirtes R and Michiels S and Barlesi F and André F and Montagnac G and Pistilli B},
  year = {2026},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2026.03.017},
  url = {https://doi.org/10.1016/j.ccell.2026.03.017}
}

RIS

TY  - JOUR
TI  - Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.
AU  - Planchard D
AU  - Cozic N
AU  - Mosele MF
AU  - Corcos N
AU  - Le Bescond L
AU  - Pradat Y
AU  - Ghigna MR
AU  - Nachabeh G
AU  - Alfaro A
AU  - Catelain C
AU  - Job B
AU  - Mami-Chouaib F
AU  - Badel S
AU  - Corgnac S
AU  - Farace F
AU  - Oulhen M
AU  - Kannouche P
AU  - Ngoc Tran DT
AU  - Droin N
AU  - Wislez M
AU  - Chouaid C
AU  - Curcio H
AU  - Cousin S
AU  - Mascaux C
AU  - Cadranel J
AU  - Geier M
AU  - Cheikh-Hussin R
AU  - Guyader P
AU  - Signolle N
AU  - Godefroy K
AU  - Talbot H
AU  - Vakalopoulou M
AU  - Christodoulidis S
AU  - Bernard E
AU  - Koudou Y
AU  - Camara V
AU  - Belarkemi A
AU  - Klein A
AU  - Morretton JP
AU  - East P
AU  - Chiaverelli R
AU  - Zwirtes R
AU  - Michiels S
AU  - Barlesi F
AU  - André F
AU  - Montagnac G
AU  - Pistilli B
PY  - 2026
JO  - Cancer cell
DO  - 10.1016/j.ccell.2026.03.017
UR  - https://doi.org/10.1016/j.ccell.2026.03.017
ER  -

APA

D, P., N, C., MF, M., N, C., L, L. B., Y, P., MR, G., G, N., A, A., C, C., B, J., F, M., S, B., S, C., F, F., M, O., P, K., DT, N. T., N, D., M, W., C, C., H, C., S, C., C, M., J, C., M, G., R, C., P, G., N, S., K, G., H, T., M, V., S, C., E, B., Y, K., V, C., A, B., A, K., JP, M., P, E., R, C., R, Z., S, M., F, B., F, A., G, M., & B, P. (2026). Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.. Cancer cell. https://doi.org/10.1016/j.ccell.2026.03.017

Source records